RE:RE:RE:Upcoming valuation on a jv deal Less than 3 months after this statement, some already expect a jv deal????
That's not understanding the process and how long such process takes.
- seeking formal interest to all big pharmas
- waiting for replies,
- analyzing offers,
- back and forth negociations,
- ensuring all have replied (positively or negatively),
- narrowing down the number of candidates,
- final negociations,
- final agreement
So nothing before 2024 as this is a lenghtly process.
TLT was not open for business before 2023, as per its 2015 vision to go all alone until Ph. 2, because of what they thought was a very promising scientific platform. They were right on, when looking at where we stand today on efficacy and low number of treatments versus competitors.
So a jv is the game plan. Couldn't be clearer than that. And that's the best route to favor initially has we have no sales network and building one we prove too be costly and very long to put in place and make it productive.
June 6, 2023 ...
Matthew Perraton, PFP, FMA, FCSI, Pro. Dir., Chairman of the Board of Theralase®, stated, "We are thrilled to welcome an individual of this caliber to our Board. Dr. Lbiati possesses a wealth of international experience across all aspects of drug development, from: clinical research to medical affairs, marketing to commercialization of various drug candidates. Her expertise comes at an opportune time, as we have made great strides in our Phase II BCG-Unresponsive NMIBC clinical study ("Study II"), whose strong interim clinical data verifies that light-activated Ruvidar™ is a potent Photo Dynamic Compound ("PDC") that is capable of destroying high-grade bladder cancer and providing a durable response to this disease, while providing a very high safety profile for the treated patient. Based on this latest interim clinical data, the Company is commencing to actively explore international partnering, licensing and distribution opportunities for our cancer targeting PDC, Ruvidar™."